Table 1 Primers used to quantify gene expression levels
From: Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Forward 5′→3′ | Reverse 5′→3′ | |
|---|---|---|
Human primers | ||
VEGFA | CTAACACTCAGCTCTGCCC | ACACACAAATACAAGTTGCCAA |
GAPDH | TCCTCCACCTTTGACGCTG | ACCACCCTGTTGCTGTAGCC |
β-actin | CATCCCCCAAAGTTCACAAT | ATGGCAAGGGACTTCCTGTA |
β-2 microglobulin | TTCTACTTTGAGTGCTGTCTCCA | ATTCTCTGCTCCCCACCTCT |
Mouse primers | ||
VEGFA | ACACGGTGGTGGAAGAAGAG | GGAAGGGAAGATGAGGAAGG |
VEGF-B | TATCTCCCAGAGCTGCCATC | CCCAAATCCCGTTATTGGTA |
VEGFR-2 | GGCAGTGTCTGAGGGTTCTC | TGGAGAGCAAACCAACCAAT |
CD31 | CGGTTTCCTAAGGTCTGAGC | GAGAAGGCGAGGAGGGTTAG |
vWF | CAATGGCTCTGTCGTGTACC | CAAGGGAGGGATCTGGTTTT |
GAPDH | TGGCATCCTTGCTTACACAG | GCAATTCCAGCCTTAGCATC |
β-actin | AATTTCTGAATGGCCCAGGT | GCTGCCTCAACACCTCAAC |
β-2 microglobulin | GCACGCAGAAAGAAATAGCA | CAGAGGGTTTGGCATATGAT |